ERYP vs. ITOS, TECX, VIGL, HUMA, SLDB, OCGN, AURA, CMPX, ALLO, and GLUE
Should you be buying ERYTECH Pharma stock or one of its competitors? The main competitors of ERYTECH Pharma include iTeos Therapeutics (ITOS), Tectonic Therapeutic (TECX), Vigil Neuroscience (VIGL), Humacyte (HUMA), Solid Biosciences (SLDB), Ocugen (OCGN), Aura Biosciences (AURA), Compass Therapeutics (CMPX), Allogene Therapeutics (ALLO), and Monte Rosa Therapeutics (GLUE). These companies are all part of the "biological products, except diagnostic" industry.
ERYTECH Pharma vs. Its Competitors
ERYTECH Pharma (NASDAQ:ERYP) and iTeos Therapeutics (NASDAQ:ITOS) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, institutional ownership, valuation, risk, analyst recommendations, profitability, dividends and earnings.
ERYTECH Pharma's return on equity of 0.00% beat iTeos Therapeutics' return on equity.
In the previous week, iTeos Therapeutics had 1 more articles in the media than ERYTECH Pharma. MarketBeat recorded 1 mentions for iTeos Therapeutics and 0 mentions for ERYTECH Pharma. ERYTECH Pharma's average media sentiment score of 0.00 equaled iTeos Therapeutics'average media sentiment score.
iTeos Therapeutics has a consensus target price of $15.86, indicating a potential upside of 57.94%. Given iTeos Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe iTeos Therapeutics is more favorable than ERYTECH Pharma.
ERYTECH Pharma has higher earnings, but lower revenue than iTeos Therapeutics.
ERYTECH Pharma has a beta of 2.69, indicating that its share price is 169% more volatile than the S&P 500. Comparatively, iTeos Therapeutics has a beta of 1.51, indicating that its share price is 51% more volatile than the S&P 500.
1.1% of ERYTECH Pharma shares are owned by institutional investors. Comparatively, 97.2% of iTeos Therapeutics shares are owned by institutional investors. 1.9% of ERYTECH Pharma shares are owned by insiders. Comparatively, 12.5% of iTeos Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Summary
iTeos Therapeutics beats ERYTECH Pharma on 8 of the 12 factors compared between the two stocks.
Get ERYTECH Pharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for ERYP and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding ERYP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
ERYTECH Pharma Competitors List
Related Companies and Tools
This page (NASDAQ:ERYP) was last updated on 6/26/2025 by MarketBeat.com Staff
